Two novel agents targeting angiopoietin-like protein 3 demonstrated safety and lipid-lowering capabilities in phase 2 trials, ...

A Phase III trial of the antisense agent mipomersen in patients with ... in levels of low-density lipoprotein (LDL)–cholesterol after 26 weeks of treatment. Mipomersen — which is being ...

It is mediated by iron molecules, with the cell dying through the degradation of the phospholipid bilayer by oxidation, a process called lipid peroxidation. However, recent studies have shown that ...

In the realm of medical diagnostics, blood lipid analysis and clinical diagnostic enzymes play a pivotal role in understanding and managing various health conditions. As key components in assessing ...